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Sllmruary 
Secretory granules of human dermal mast cells contain a chymotrypsin-like serine proteinase called 
chymase. In this study, we demonstrate that the inactive cytokine, 31 kD interleukin 18 (IL-lfl), 
can be converted rapidly to an 18 kD biologically active species by human mast cell chymase. 
The product formed is three amino acids longer at the amino terminus than the mature IL-lfl 
produced by peripheral blood mononuclear cells and has comparable biological activity. Because 
chymase is a secretory granule constituent, it is likely to be released into the surrounding tissue 
when mast cells degranulate.  It is also known that non-bone marrow derived cells resident in 
skin (keratinocytes, fibroblasts) produce but do not process 31 kD IL-I~. In this context, chymase 
may be a potent activator of locally produced 31 kD IL-lfl. Mast cells lie in close apposition 
to blood vessels in dermis;  therefore, chymase mediated conversion of 31 kD IL-1/~ might be 
expected to have a critical role in the initiation of the inflammatory response in skin. 
I 
t  has recently become clear that many important cyto- 
kines can be released from cells as biologically  inactive 
precursor molecules. TGF-B and IL-lfl both require post trans- 
lational proteolytic processing to attain activity in vitro (1, 
2). Biologically inactive precursor 31 kD IL-I~/can be con- 
verted to an active 17 kD (NH2-terminal  Ala 117) molecule 
by a convertase enzyme recently isolated from monocytes (3, 
4). Paradoxically, many cells that make 31 kD IL-I~/do not 
contain such convertase activity and are unable to generate 
an active species of IL-lfl (5, 6). We have recently demon- 
strated that 31 kD IL-fl produced by human epidermal ker- 
atinocytes can be cleaved by exogenous chymotrypsin into 
biologically  active 18 kD IL-1B species (NH2-terminal  Val 
114) (5). Based on these and other data, we postulated  that 
the processing of 31 kD IL-1B produced by non-bone marrow 
derived cells occurs extracellularly. 
Human mast cell chymase is a chymotrypsin-like proteinase 
stored within the secretory granules of a subset of human 
mast cells termed MCTc; this mast cell designation signifies 
the presence of two different serine proteinases referred to 
as human chymase (C) and tryptase  (T). MCTc mast cells 
are the predominant mast cell type found in skin and gut 
submucosal tissues whereas MCT mast cells containing only 
tryptase predominate in lung alveoli and gut mucosa. Mast 
cell degranulation is the initial event in IgE-mediated inflam- 
matory responses and has been implicated in various skin dis- 
eases (7). More recently, mast cell degranulation has been 
cited as an early event in cutaneous inflammatory reactions 
(8), in part because of release of preformed TNF-~x, an im- 
portant regulator in endothelial adhesion molecule expres- 
sion. Because mast cell degranulation can be induced by di- 
verse stimuli mast cell mediators may have a wider general 
role in acute and chronic inflammatory responses (8). 
MCTc type mast cells reside in several distinct tissues, in- 
cluding the dermis (9). As such, they are in close proximity 
to many cells capable of producing (but not processing) 31 
k.D IL-1B. Demonstration of the processing of 31 kD-1B 
by mast cell chymase provides a pathway for the activation 
of this material. Since IL-1 (like TNF-c~) is also a potent regu- 
lator of adhesion molecule expression by endothelial  cells, 
this model would provide an important mechanism whereby 
mast cell products could initiate an immune or inflamma- 
tory response. 
Material and Methods 
Purification  of  Mast Cell Chymase.  Human chymase  was purified 
from human skin as previously  described (10, 11). Skin was ex- 
tracted first in low and then in high ionic strength solutions. The 
latter solution solubilizes chymase  and tryptase. The extract was 
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matographed on heparin-Sepharose (12). Tryptase and chymase bind 
to the column and were eluted in a single  step with 2 M NaC1. 
The 2 M NaC1 eluate was then chromatographed on soybean trypsin 
inhibitor-Sepharose. Chymase but not tryptase binds to this resin. 
Chymase was  eluted from the column using  1.0 mM HC1. 
Interleukin 1.  Recombinant "mature" or 17-kD human IL-lfl 
encoded by the latter half of the IL-lfl cDNA (codons 117-269) 
was synthesized in a prokaryotic expression  vector under control 
of a temperature sensitive repressor (13). The protein was extracted 
from Escherichia coli and purified to homogeneity by sequential 
sulfopropyl sephadex,  DEAE, and Procion Red column chroma- 
tography (Bethesda  Research Laboratories,  Gaithersburg, MD) as 
described (13). Expression of recombinant "precursor", 31-kD or 
"pro-IL-13" involved the use of a full length (codons 1-269) IL-lfl 
cDNA using the same temperature sensitive repressor (14). After 
lysis of bacteria,  31-kD  IL-lfl was  purified using  sequential Q 
Sepharose, Procion Red, and Phenyl-Sepharose  CL-4B chromatog- 
raphy as previously described  (14). 
IL-I Biological  Assay.  The assay to detect IL-1 activity utilizes 
the T cell clone D10.G41 and the clonotype-specific  mAb 3D3 and 
has  been  described in  detail  (15, 16).  6  h  before harvest  (3H)- 
thymidine (1/zCi per well;  1 Ci  =  37 GBq) was added.  Triplicate 
cultures were harvested on an automated sample harvester (Cam- 
bridge Technologies, Inc., Boston, MA) and radioactivity was mea- 
sured with an LKB scintillation spectrometer (LKB Instruments, 
Inc.,  Gaithersburg, MD). 
lmmunobtotting.  Western blot analysis was  performed as de- 
scribed previously in detail (5). Samples were loaded on to a 13% 
polyacrylamide gel containing 0.1%  SDS under reducing condi- 
tions. After etectrophoresis, proteins were transferred onto nitrocel- 
lulose membranes (Bio-Rad Laboratories, Richmond, CA) in a trans- 
blot cell apparatus  (Bio-Rad Laboratories).  The blot was blocked 
with dry milk and then incubated for 1 h with monoclonal anti-IL-1 
antibody (M3; reference 5) diluted in 0.05%  Tween 20  10 mM 
tris-buffer  (pH  8.0)  (TBST).  After washing  in  TBST,  alkaline 
phosphatase-conjugated goat anti-mouse IgG antibody (Promega 
Biotec, Madison, WI) was added and the blot was developed and 
photographed. 
Amino Acid Sequencing.  SDS-PAGE electrophoresis was  per- 
formed as in Fig. 2. Protein was transferred onto FVDF membranes 
(Immobilon) (17) and subjected to amino acid sequence determina- 
tion using an Applied Biosystems 470A gas phase sequencer (Ap- 
plied Biosystems,  Foster City, CA). 
Figure 1.  SDS-PAGE  analysis of purified human chymase. Lanes 2, 3, 
and 4 contain 1.5, 2.5, and 5.0/~g chymase  respectively.  One major band 
is resolved  migrating at an apparent Mr of 30,000. In analyses  of other 
preparations, it was shown that the protein in this band represents  mate- 
rial that can be labeled with radioactive  DFP, an inhibitor of serine pro- 
teinases. The broadness of the band is due to glycosylation. 
forms of immunoreactive  IL-lfl.  At  the conclusion of the 
assay,  a homogeneous immunoreactive band is present at 18 
kD. This species of IL-lfl is resistant to further cleavage, even 
if the reaction is allowed to proceed for several hours.  It can 
be appreciated that several immunoreactive IL-lfl species of 
intermediate mol wt are generated by chymase cleavage, and 
analysis of the amino acid sequence of 31 kD IL-lfl indicates 
that several putative chymotrypsin cleavage sites exist between 
the  NH2-terminal  of 31  kD  IL-lfl  and  the  NH2-terminal 
Ala  117  of the mature  molecule (19). 
Results 
Purified mast cell chymase migrated as a single protein spe- 
cies of 30 kD  on a SDS-PAGE gel (Fig.  1) and maintained 
significant enzymatic activity in vitro on chymotryptic sub- 
strates (18). The broadness of the band is thought to be due 
to variable glycosylation. We next determined whether this 
enzymatically active, highly purified mast cell chymase from 
human  skin mast  cells could cleave highly purified recom- 
binant human 31 kD IL-lfl.  IL-lfl was identified by Western 
blot using an antibody to a carboxy-terminal peptide common 
to all forms of IL-lfl as previously described (5). Fig. 2 indi- 
cates  that  cleavage of the  precursor  molecule by mast  cell 
chymase occurs almost instantaneously and is essentially com- 
plete by 30 rain. Formal analysis of the kinetics of the reac- 
tion are complicated by the appearance of multiple intermediate 
Figure 2.  Western  blot analysis of cleavage products of 31 kD IDlfl 
generated by mast cell chymase. Lane I, 31 kD recombinant IL-lfl; lanes 
2-8, 31 kD Iblfl incubated  with mast cell  chymase  for the indicated  number 
of minutes. 31 kD Iblfl (10/~g) and mast cell chymase (100 pg) were 
incubated at 37~  for the indicated times. The reaction was stopped by 
boiling in sample buffer. Western blotting was performed as described  in 
detail in reference  4. Samples  were dectrophoresed on a 13% SDS-PAGE 
gel and transferred to nitrocellulose using a transblot cell. M3 mAb to 
Ib13 was used for blotting. 
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Figure 3.  NH2 terminal sequence analysis of the final cleavage  product 
(18-kD protein) of 31 kD IL-13 mast cell chymase. The sequence  obtained 
is on the line below the amino acid sequence deduced from the eDNA 
sequence  of full length 31 kD II.-13. Identity is observed  through 20 cycles. 
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Figure 4.  Chymase  cleavage  of 31 kD IL-1B  generates a species oflI~l~ 
with activity comparable  to 17 kD recombinant  IL-1B. Samples were mixed 
at various dilutions with 2  x  104 D10.G4.1 cells (American Type Cul- 
ture Collection, Rockville, MD) and 3D3 antibody in triplicate cultures 
as described previously (5). Incorporation of 3H thymidine into cellular 
DNA was assessed at 72 h by scintillation spectrometry. 
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Figure 5.  II.-1 activity of the 18-kD protein can be neutralized using 
antibodies to rlL-13. A neutralizing polyclonal rabbit antiserum to IL-13 
was used at a 1:200 dilution. While 2 pg/ml of pro-IL-1B  had no activity 
in this assay, the same amount ofchymase digested pro-IL-1 had significant 
activity. All activity was blocked upon the inclusion of anti-lL-13. 
The putative chymotryptic cleavage site nearest to the N- 
terminal  aspect  of mature  17 kD  IL-1B appears  to be Tyr 
113-Val 114. Since conversion of 31 kD IL-13 to the 18 kD 
species was complete by 60 rain, peptide sequencing was per- 
formed on this  product.  Fig.  3  indicates  that  a  single pre- 
dominant sequence was obtained consistent with an 18-kD 
fragment  of IL-1~8 whose NH~-terminus  matched Val  114 
of the full length precursor. Identity between the 18 kD frag- 
ment and the sequence of 31 kD IL-13 distal to Tyr 113 was 
found through the first 20 cycles. No other sequences consis- 
tent with IL-13 fragments of different tool wt were identified. 
Therefore, it appears that Tyr 113-Val 114 is indeed the most 
distal  site  susceptible to chymase cleavage. 
We next asked whether this 18-kD fragment of IL-1B had 
significant IL-1 biological activity, using the IL-4-producing 
D10.G4.1  T  helper cell clone as our assay (5,  16).  Results 
of a representative experiment are shown in Fig. 4. Mast cell 
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31 kD IL-I~ had no demonstrable activity in the assay at 
concentrations of between .02 and 20 pg/ml, as has been 
demonstrated by us and others previously (5, 14). However, 
significant biological activity could be demonstrated with con- 
centrations of the 18-kD chymase generated IL-1/~ fragment 
as low as 2 pg/ml; this activity was comparable to the ac- 
tivity of authentic 17 kD mature IL-1/~, in the same assay. 
Therefore, we conclude that the 18-kD protein (N-terminal 
Val 114) generated by the cleavage of 31 kD IL-1B by mast 
cell chymase is no less biologically active than authentic recom- 
binant 17 kD IL-I~ (NH2-terminal Ala 117). Finally, we 
asked whether the IL-1 activity of the 18-kD protein could 
be neutralized by a polyclonal antibody to IL-1B. Fig. 5 shows 
that the 18-kD protein (but not 31 kD IL-1/~ or mast cell 
chymase) has significant  activity in the D10 assay. This ac- 
tivity was neutralized completely by blocking antibodies to 
IL-I . 
Discussion 
These data indicate clearly that human dermal mast cell 
chymase can generate a stable product from inactive 31 kD 
IL-1/3 that has biological activity comparable to that of recom- 
binant 17 kD IL-1B. The potential importance of this inter- 
action relates to the fact that the monocyte convertase en- 
zyme cannot be found in cells resident  to  skin,  such as 
fibroblasts and keratinocytes (5, 6). Both of these important 
cellular  constituents of skin have been shown to produce 
mRNA and 31-kD protein identical to IL-1/~ and without 
IL-1 biological activity. Thus, proteolytic enzymes released 
by cells into the extracellular space might be expected to cleave 
31 kD IL-1/3 released from such cells. 
Activity of cleavage products of IL-I~ diminishes rapidly 
as the cleavage site moves towards the NH2 terminus of the 
precursor; chymotrypsin cleavage generates a molecule three 
amino acids longer than mature IL-1/~ with comparable bio- 
logical activity.  In contrast,  elastase and trypsin cleavage 
generate molecules 13 and 41 amino acids longer than ma- 
tare IL-1B, respectively (14); however, both molecules have 
less than 2% of the biological activity of mature IL-1B. We 
have found cathepsin G, a neutrophll protease with chymo- 
tryptic specificity, inefficient  at cleaving 31-kD IL-13 into 
a biologically active species (our unpublished data).  Thus, 
it would appear that the number of biologically relevant pro- 
teases capable of converting 31 kD IL-I•  into an active spe- 
cies is limited. 
While some 31 kD IL-13 can be released by uninjured 
cells, the majority remains in a cell associated compartment. 
Under what conditions might mast cell chymase encounter 
31 kD IL-1B? Injury (mechanical, thermal, radiant, or inflam- 
matory) to skin can damage or even disrupt cells, thus releasing 
intracellular 31 kD IL-1B. Injury is a well known stimulus 
to mast cell degranulation, and it would be predicted that 
such a combination of events would lead to generation of 
active IL-13 via chymase induced cleavage of 31 kD IL-13. 
In turn, this would lead to a series of events including induc- 
tion of endothelial adhesion molecules (thus trapping leuko- 
cytes),  and the simultaneous production of IL-1 inducible 
cytokines with chemotactic and leukocyte activating proper- 
ties by cells resident to skin (reviewed in reference 21). 
The chymase generated 18 kD IL-I~ may be a contributing 
cytokine in the observed expression of endothelial adhesion 
molecules after mast cell degranulation (10). ELAM-1 was 
recently identified as a relatively skin specific endothelial cell 
receptor for a ligand on memory T cells (22), providing an 
important mechanism for recruiting such cells to sites of cu- 
taneous injury and antigenic challenge. Another role for mast 
chymase may be to cleave preformed or induced 31 kD IL-13 
produced by mast cells themselves. While attractive, this latter 
possibility remains speculative, and human dermal mast cells 
are currently being analyzed  for 31 kD IL-1B production. 
In summary, we and others have recently demonstrated the 
production of 31 kD IL-13 by cells that are apparently un- 
able to process this molecule into a biologically active form 
(5).  Identification of proteases,  such as mast cell chymase, 
that can generate active IL-13 from the inactive precursor 
may help define how adjacent cells and tissues can function 
as a whole to induce a complex biological phenomenon such 
as inflammation. 
We are grateful to David McCourt for performing the amino acid analysis, and to Ginger Roberts for 
preparing the manuscript. 
This work was funded in part by National Institutes of Health grants AI-25082 and AR-40124. 
Address correspondence  to Thomas S. Kupper, Division of Dermatology, Departments of Medicine and 
Pathology, Washington University School of Medicine, Box 8123, 660 South Euclid Avenue, St. Louis, 
MO 63110. 
Received for publication 25 April 1991 and in revised  form  13 June  1991. 
824  Rapid  and Specific Conversion  of Precursor Interleukin  1/~ References 
1.  Mosley, B., D. Urdal, K. Prickett, A. Larsen, D. Cosman, P. 
Conlon,  S. Gillis, and S.K. Dower. 1987. The interleukin-1 
receptor binds the human interleukin-lot precursor but not 
the intedeukin-13  precursor. J. Biol. Chem.  262:2941. 
2.  Miyzano, K., U. Hellman, C. Wernstedt, and C.H. Heldin. 
1988. Latent high molecular weight complex of transforming 
growth factor 31. J. Biol. Chem.  263:6407. 
3.  Black, R., S. Kronheim, and P. Sleath. 1989. Activation of 
interleukin-13 by a co-induced protease. FEBS Lett. 247:386. 
4.  Kostura, M.J., J. Toccis, G. Limjuco, J. Chin, P. Cameron, 
A. Hillman, D. Chartrain, andJ. Sehmidt. 1989. Identification 
of  monocyte specific  pre-interleukin  13 convertase  activity.  Proc 
Natl. Acad. Sci. USA.  86:1066. 
5.  Mizutani, H., R. Black, and T.S. Kupper. 1991. Human ker- 
atinocytes produce but do not process pro-interleukin-1 (IL-1) 
beta. J.  Clin.  Invest. 87:1066. 
6.  Elias,  J, M. Reynolds, R. Kotyloff, andJ. Kern. 1989. Fibro- 
blast interleukin 13: Synergistic stimulation by recombinant 
intedeukin I and tumor necrosis factor and posttranscriptional 
regulation. Pro~ Natl. Acad. Sci. USA.  86:6171. 
7.  Stevens, R.L., and K.F. Austen. 1989. Recent advances in the 
cellular and molecular biology of mast cells. Immunol.  Today. 
10:381. 
8.  Klein, L.M., R.M. Lavker,  W.L Marls, and G.F. Murphy. 1989. 
Degranulation of human mast cells induces an endothelial an- 
tigen central to leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 
86:8972. 
9.  Irani, A.A., N.M. Schechter,  S.S. Craig, G. DeBlois, and L.R 
Schwartz. 1986. Detection of MCT and MC~c types human 
mast cells by immunohistochemistry using new monoclonals 
anti-tryptase  and  anti-chymase antibodies. J.  Histochem. 
CI/tochem. 37:1509. 
10.  Schechter, N.M., J.E.  Fraki, J.C.  Geesin, and G.S. Lazarus. 
1983. Human skin chymotryptic proteinase. J. Biol. Chem. 
258:2973. 
11.  Sehechter,  N.M., D. Slavin, R.D. Feuer, G.S. Lazarus,  andJ.E. 
Fraki. 1988. Purification and identification of two serine class 
proteinases from dog mast cells biochemically and immuno- 
logically similar to human proteinases tryptase and chymase. 
Arch.  Biochem. Biophys. 262:232. 
12.  Sayama,  S., R.V. Iozzo, G.S. Lazarus, and N.M. Sehecter. 1987. 
Human skin chymotrypsin-like proteinase chymase,  f  Biol. 
Chem.  262:6808. 
13.  Kronheim, S.M., M.A. Cantrell, M.C. Deeley, C. March, P. 
Glackin, D. Anderson, T. Hemenway,  J. Merriam, D. Cosman, 
and T. Hoop. 1986. Purification to homogeneity of Ibl beta 
protein. Biotechnology. 4:1978. 
14.  Black, R., S. Kronheim, M. Cantrell, M. Deely, C. March, 
K. Prickett, J. WignaU, p. Conlon, D. Cosman, T. Hoop, and 
D. Mochizuki. 1988. Generation of biologically active inter- 
leukin-13 by proteolytic cleavage of the inactive precursor.  J. 
Biol. Chem.  263:9437. 
15.  Kaye,  J., S. Gillis, S. Mizel, E. Shewach, T. Malck, C. Dinarello, 
L. Lackman, and C. Janeway. 1984. Growth of  a cloned helper 
T cell line induced by a monoclonal antibody specific  for the 
antigen receptor: Interleukin 1 is required for the expression 
of receptors for interleukin 2. J. Immunol.  133:1339. 
16.  Mizutani, H., L. May, P. Sehgal, and T. Kupper. 1989. Syner- 
gistic interaction of IL-1 and IL-6 in T cell activation: mitogen 
but not antigen receptor induced proliferation of a cloned T 
helper cell line is enhanced by exogenous IL-6.  J. Immunol. 
143:896. 
17.  Matsudiara,  P. 1987. Sequence  from picomole  quantities of  pro- 
teins electroblotted onto polyvinylidene  difluoride  membranes. 
J. Biol. Chem.  262:10035. 
18.  Powers, J.C., T. Tanaka, W. Haper, et al. 1985. Mammalian 
chymotrypsin-like  enzymes. Comparative  reactivities  of  rat cell 
proteases, human and dog skin chymases,  and human cathepsin 
G with peptide 4-nitroanilide  substrates and with peprldes chlo- 
romethyl ketone and sulfonyl fluoride inhibitors. Biochemistry. 
24:2048. 
19.  March, C., B. Mosley,  A. Larsen,  et al. 1985. Cloning, sequence 
and expression of two distinct human interleukin-1 complemen- 
tary DNAs. Nature (Lond.). 315:641. 
20.  Hazuda, D., J. Strickler, F. Kueppers, P. Simon, and P. Ypung. 
1990. Processing of precursor interleukin 13 and inflamma- 
tory disease, f  Biol. Chem.  265:6318. 
21.  Kupper, T.S. 1990. Immune and inflammatory processes in cu- 
taneous tissues. J.  Clin.  Invest. 86:1783. 
22.  Picker,  L.J., T.K. Kishimoto, C.W. Smith, 1L.A.  Warnock, and 
E.C. Butcher. 1991. ELAM-1 is an adhesion molecule for skin- 
homing T cell. Nature (Lond.). 349:796. 
825  Mizutani  et al. 